TFX on NYSE

Teleflex

Logo: Teleflex Incorporated, Public domain, via Wikimedia Commons5

American medical device company

Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures.3 Its shares trade on NYSE under the symbol TFX.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1943Founded1

Compare with ICU Medical, INTEGRA LIFESCIENCES HOLDINGS CORP or MERIT MEDICAL SYSTEMS INC, or pick any stock.

  • TickerTFX on NYSE1
  • Industrymedical device design1
  • HeadquartersWayne1
  • Websitewww.teleflex.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address550 E Swedesford Rd, Suite 400, Wayne, Pa 190876
  • Filer categoryLarge accelerated filer6
  • LEIUUL85LWXB4NGSWWXIQ254
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O THE PRENTICE-HALL CORPORATION SYSTEM, INC., 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 3864214

Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has operations in 40 countries, and more than 15,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with Irish corporate tax avoidance tools. Teleflex's chief executive officer (CEO) and president is Jason Weidman.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

56.2%Gross margin9
5.9%Operating margin9
-45.4%Net margin9
17.2%Revenue growth, 20259
-29.0%Return on equity9
0.81×Debt to equity9

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Vascular Access brought in 46% of the revenue Teleflex broke down this way in fiscal 2025.

  1. Vascular Access$917.7M946%up 2% from 2024
  2. Interventional$647.8M933%up 63% from 2024
  3. Surgical$418.2M921%up 3% from 2024
  4. Other$9.0M90%up 246% from 2024
Products and services by year
Products and services202320242025
Vascular Access$841.1M$903.5M$917.7M
Interventional$407.3M$397.3M$647.8M
Surgical$388.3M$404.9M$418.2M
Other$75.8M-$6.2M$9.0M

Business segments

Americas brought in 64% of the revenue Teleflex broke down this way in fiscal 2025.

  1. Americas$1.3B964%up 11% from 2024
  2. EMEA$472.4M924%up 39% from 2024
  3. Asia$241.1M912%up 19% from 2024
Business segments by year
Business segments202320242025
Americas$1.2B$1.2B$1.3B
EMEA$317.0M$340.3M$472.4M
Asia$214.8M$202.3M$241.1M

Regions

United States brought in 59% of the revenue Teleflex broke down this way in fiscal 2025.

  1. United States$1.2B959%up 9% from 2024
  2. Europe$484.7M924%up 39% from 2024
  3. Asia And Asia Pacific$218.0M911%up 21% from 2024
  4. All Other$108.1M95%up 17% from 2024
Regions by year
Regions202320242025
United States$1.1B$1.1B$1.2B
Europe$330.1M$347.9M$484.7M
Asia And Asia Pacific$187.9M$179.6M$218.0M
All Other$87.5M$92.7M$108.1M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue44¢$872.0M
  • Research and development7¢$144.8M
  • Selling, general and admin36¢$720.2M
  • Other costs11¢$221.8M
  • Income tax2¢$34.0M

Out of $2.0B in revenue.9 The company lost money this year.

Financial statements

Revenue101112139$2.0B in 2025−23% since 2019
0$1.0B$2.0B$3.0B2019: $2.6B$2.6B20192020: $2.5B$2.5B2020−2%2021: $2.8B$2.8B2021+11%2022: $2.8B$2.8B2022−1%2023: $1.7B$1.7B2023−39%2024: $1.7B$1.7B2024−1%2025: $2.0B$2.0B2025+17%
Gross profit101112139$1.1B in 2025−20% since 2019
0$500.0M$1.0B$1.5B$2.0B2019: $1.4B$1.4B20192020: $1.3B$1.3B2020−6%2021: $1.5B$1.5B2021+17%2022: $1.5B$1.5B2022−1%2023: $1.0B$1.0B2023−32%2024: $1.0B$1.0B2024−0%2025: $1.1B$1.1B2025+8%
Operating income101112139$118.4M in 2025−72% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $427.3M$427.3M20192020: $423.1M$423.1M2020−1%2021: $628.1M$628.1M2021+48%2022: $499.7M$499.7M2022−20%2023: $258.7M$258.7M2023−48%2024: $103.7M$103.7M2024−60%2025: $118.4M$118.4M2025+14%
Net income101112139-$905.6M in 2025
-$1.0B-$500.0M0$500.0M2019: $461.5M$461.5M20192020: $335.3M$335.3M2020−27%2021: $485.4M$485.4M2021+45%2022: $363.1M$363.1M2022−25%2023: $356.3M$356.3M2023−2%2024: $69.7M$69.7M2024−80%2025: -$905.6M-$905.6M2025

Every line of the income statement as filed: the last 3 fiscal years (annual) or 8 quarters (quarterly), latest first.9

Period ending2025-12-312024-12-312023-12-31
Net revenues$2.0B$1.7B$1.7B
Cost of goods sold$872.0M$662.2M$672.3M
Gross profit$1.1B$1.0B$1.0B
Selling, general and administrative expenses$720.2M$674.5M$622.7M
Research and development expenses$144.8M$109.0M$113.6M
Pension settlement charge$0$132.7M$45.2M
Restructuring charges, separation costs and impairment charges$137.4M$17.5M$4.2M
Gain on sale of assets and business$0$0-$4.4M
Income from continuing operations before interest and taxes$118.4M$103.7M$258.7M
Interest expense$100.2M$83.5M$85.0M
Interest income-$6.4M-$6.2M-$11.7M
Income from continuing operations before taxes$24.6M$26.3M$185.4M
(Benefit) taxes on income from continuing operations-$34.0M-$30.9M$41.9M
Income from continuing operations$58.5M$57.2M$143.5M
Operating (loss) income from discontinued operations-$1.1B$48.6M$247.0M
(Benefit) taxes on operating loss from discontinued operations-$133.0M$36.1M$34.2M
(Loss) income from discontinued operations-$964.2M$12.5M$212.8M
Net (loss) income-$905.6M$69.7M$356.3M
Income (loss) from continuing operations (in dollars per share)$1$1$3
Loss from discontinued operations (in dollars per share)-$22$0$5
Net income (in dollars per share)-$20.30$1.49$7.58
Income from continuing operations (in dollars per share)$1$1$3
(Loss) income from discontinued operations (in dollars per share)-$22$0$4
Net income (loss), diluted (in dollar per share)-$20.25$1.48$7.53
Basic (in shares)44.6M shares46.8M shares47.0M shares
Diluted (in shares)44.7M shares47.1M shares47.3M shares

Compare Teleflex with another company

Corporate structure

Teleflex sits at the top of its group. 14 entities, 11 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Teleflex

  • Teleflex Wayne, Pennsylvania, United States
    • Norland Plastics Subsidiary
    • Teleflex (Canada) Subsidiary · Markham, Canada
    • Teleflex (Germany) Subsidiary · Bad Liebenzell, Germany
    • Willy Rüsch AG Subsidiary
    • 13. Formerly Arrow Subsidiary · Japan
    • Arrow Internacional de Subsidiary · Mexico
    • BIOTRONIK AG Subsidiary · Bülach, Switzerland
    • Lotus MedTec Subsidiary · Spain
    • PT Teleflex Medical Subsidiary · Indonesia
    • Teleflex (Australia) Subsidiary · Australia
    • Teleflex Medical Subsidiary · Japan
    • TELEFLEX MEDICAL EUROPE LIMITED Subsidiary · Athlone, Ireland
    • VASC NXT Subsidiary · Portugal

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Teleflex reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$309.5M9 Dec 31, 2025$243.3M9 Dec 31, 2024+27.2%
Computer equipment and software$223.4M9 Dec 31, 2025$208.5M9 Dec 31, 2024+7.1%
Construction in progress$131.1M9 Dec 31, 2025$82.4M9 Dec 31, 2024+59.1%
Property and equipment, before depreciation$968.3M9 Dec 31, 2025$717.9M9 Dec 31, 2024+34.9%
Accumulated depreciation$470.1M9 Dec 31, 2025$409.4M9 Dec 31, 2024+14.8%
Property and equipment, net$498.3M9 Dec 31, 2025$308.5M9 Dec 31, 2024+61.5%
Operating-lease assets (leased space)$91.8M9 Dec 31, 2025$95.7M9 Dec 31, 2024−4.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$378.6M9 Dec 31, 2025$247.9M9 Dec 31, 2024+52.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$2.3B9 Dec 31, 2025$2.0B9 Dec 31, 2024+15.7%
Intangible assets, net (excluding goodwill)$1.5B9 Dec 31, 2025$1.3B9 Dec 31, 2024+13.0%
Accumulated amortization$1.3B9 Dec 31, 2025$1.1B9 Dec 31, 2024+20.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$404.4M9 Dec 31, 2025$306.8M9 Dec 31, 2024+31.8%
Raw materials$90.0M9 Dec 31, 2025$70.1M9 Dec 31, 2024+28.5%
Work in process$54.4M9 Dec 31, 2025$37.7M9 Dec 31, 2024+44.2%
Finished goods$260.0M9 Dec 31, 2025$199.0M9 Dec 31, 2024+30.7%

Properties, in its own words

We own or lease approximately 110 properties consisting of manufacturing plants, engineering and research centers, distribution warehouses, offices and other facilities. We believe that the properties are maintained in good operating condition and are suitable for their intended use. In general, our facilities meet current operating requirements for the activities currently conducted within the facilities.

Our major facilities (those with 50,000 or greater square feet) at December 31, 2025 are as follows:

The rest of Item 2

Location · Primary use · Square Footage · Owned or Leased

Olive Branch, MS · Distribution warehouse · 627,000 · Leased

Kamunting, Malaysia (1) · Manufacturing · 286,000 · Owned

Tecate Mexico · Manufacturing · 172,000 · Owned

Chihuahua, Mexico · Manufacturing · 153,000 · Owned

Morrisville, NC · Office administration · 133,000 · Leased

Zdar Nad Sazauou, Czech Republic · Manufacturing · 108,000 · Owned

Maple Grove, MN · Engineering and research · 103,000 · Owned

Trenton, GA (1) · Manufacturing · 102,000 · Owned

Chihuahua, Mexico · Manufacturing · 100,000 · Owned

Buelach, Switzerland · Manufacturing · 100,000 · Owned

Hradec Kralove, Czech Republic · Manufacturing · 92,000 · Owned

Chelmsford, MA (1) · Manufacturing · 91,000 · Leased

Kulim, Malaysia (1) · Manufacturing · 90,000 · Owned

Jaffrey, NH (1) · Manufacturing · 90,000 · Owned

Maple Grove, MN · Manufacturing · 79,000 · Leased

Kamunting, Malaysia (1) · Manufacturing · 77,000 · Leased

Pleasanton, CA · Mixed use · 76,000 · Leased

Nuevo Laredo, Mexico (1) · Manufacturing · 71,000 · Leased

Chihuahua, Mexico · Manufacturing · 63,000 · Owned

Reading, PA · Engineering and research · 63,000 · Leased

Buelach, Switzerland · Office administration · 62,000 · Leased

Limerick, Ireland (1) · Manufacturing · 58,000 · Owned

Wayne, PA · Office administration · 58,000 · Leased

Mansfield, MA (1) · Manufacturing · 57,000 · Leased

Plymouth, MN (1) · Manufacturing · 55,000 · Leased

(1) Property is held for sale and classified as discontinued operations as of December 31, 2025.

Operations in each of our business segments are conducted at locations both in and outside of the U.S. Of the facilities listed above, our facilities generally serve more than one business segment and are often used for multiple purposes, such as administrative/sales, manufacturing and warehousing/distribution.

In addition to the properties listed above, we own or lease approximately 750,000 square feet of additional warehousing, manufacturing and office space worldwide.

Item 2 of the 10-K filed Feb 27, 2026.17

The story

Teleflex was founded in 1943. Over time the business expanded into a conglomerate operating in multiple markets, often through acquisitions, such as:

Franklin Medical Ltd (1985)

Warne Surgical Products Ltd (1985)

Willy Rüsch AG (1989)

Pilling (1991)

Access Surgical (1993)

Nextex (1993)

Unimed (1994)

Read the full text

General Medical OEM Division (1994)

Europe Medical (1994)

Fehling (1994)

Simal (1994)

Endoscopy Specialists, Inc. (1995)

Asid Bonz (1996)

Comcorp Technologies, Inc. (1997)

Z-Medica (2020)

In general these acquisitions moved the business further into the design, build and supply of medical devices, a move that had begun in 1981 with the construction of the Applied Polymer plant in New Hampshire. Several acquisitions were not in line with this strategy. Comcorp, for example, was a supplier of pedals and other components for passenger cars and light-duty trucks and Nextex a fiber-optic communications business.

Refocus on the medical device sector began in March 2009 when Teleflex sold its marine and industrial instrumentation (gauge) business to Veethree, and planned to exit its Lakewood Ranch, Florida facility. Veethree subsequently continued production of former Teleflex products at its Manatee County, Florida facility and hired approximately 50 workers from Teleflex.

In March 2011, Teleflex sold its marine division, Teleflex Marine, to H.I.G. Capital.

In August 2012, Teleflex substantively finalized an agreement to acquire all assets of the medical device maker LMA International, thereby expanding the company's anesthesia device franchise.

In December 2013, Teleflex completed the acquisition of Vidacare Corporation, integrating Vidacare's intraosseous EZ-IO and OnControl medical devices into Teleflex's Arrow product line.

On September 5, 2017, Teleflex announced that it had entered into a definitive agreement to acquire NeoTract in a transaction valued at up to $1.1B USD. Under the terms of the agreement, Teleflex will acquire NeoTract for an up-front cash payment of $725M USD and up to an additional $375M USD contingent on the achievement of certain sales-related commercial milestones through December 31, 2020. The transaction was unanimously approved by the Boards of Directors for both Teleflex and NeoTract.

On January 18, 2019, S&P Dow Jones Indices added Teleflex to its S&P 500 stock market index, replacing PG&E in the index after the utility company declared bankruptcy.

On March 24, 2025, S&P Dow Jones Indices removed Teleflex from its S&P 500 stock market index.

From Wikipedia’s article on Teleflex, shared under CC BY-SA 4.0.7

Leadership

Who has led Teleflex, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (57)

Subsidiaries and ownership

Subsidiaries

Subsidiaries (Exhibit 21)

  • 13. Formerly Arrow Japan, Ltd.8
  • Arrow Internacional de Mexico, S.A. de C.V.8
  • Lotus MedTec Spain, S.L.U.8
  • PT Teleflex Medical Indonesia8
  • Teleflex Medical Japan, Ltd. 138
  • VASC NXT Portugal, Unipessoal Lda8

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Sep 9, 20268-K Executive or director change; Regulation FD disclosure90
  2. Aug 7, 20268-K Other events91
  3. Aug 6, 20268-K Results of operations; Regulation FD disclosure92
  4. Aug 5, 20268-K Financial statements and exhibits93
  5. Aug 3, 20268-K Completed an acquisition or sale; Regulation FD disclosure94
  6. Jun 15, 20268-K Entered a material agreement; New debt or obligation95
  7. Jun 9, 2026New chief executive Jason R. Weidman becomes CEO19
  8. Jun 9, 20268-K Executive or director change96
  9. Jun 2, 20268-K Other events97
  10. Jun 1, 20268-K Regulation FD disclosure; Other events98
  11. May 27, 20268-K Entered a material agreement; New debt or obligation99
  12. May 20, 20268-K Shareholder vote100
  13. May 7, 20268-K Results of operations; Regulation FD disclosure101
  14. Jan 15, 2026New chief executive Stuart A. Randle becomes CEO18
  15. Feb 27, 2018New chief executive Liam Kelly becomes CEO20
  16. Mar 1, 2011New chief executive Benson Smith becomes CEO21
  17. Oct 27, 2003New chief executive Jeffrey P. Black becomes CEO22
  18. Jan 2, 1990Went public Listed on NYSE1
  19. 1943Founded Founded1

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $3.67 a share, on Nov 6, 2025.102

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results92
  2. May 7, 2026Reported quarterly or annual results101
  3. Feb 26, 2026Reported quarterly or annual results103
  4. Jan 8, 2026Reported quarterly or annual results104
  5. Nov 6, 2025Reported quarterly or annual results105
  6. Jul 31, 2025Reported quarterly or annual results106
  7. May 1, 2025Reported quarterly or annual results107
  8. Feb 27, 2025Reported quarterly or annual results108

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

295 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 52 major events, 154 insider forms, 40 large holders, 29 other. The latest 20:

  1. Sep 10, 20264 EDGAR
  2. Sep 10, 20263 EDGAR
  3. Sep 9, 20268-K EDGAR
  4. Sep 8, 2026SCHEDULE 13G/A EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 7, 20268-K EDGAR
  7. Aug 6, 202610-Q EDGAR
  8. Aug 6, 20268-K EDGAR
  9. Aug 5, 20268-K/A EDGAR
  10. Aug 3, 20268-K EDGAR
  11. Jun 26, 202611-K EDGAR
  12. Jun 15, 20268-K EDGAR
  13. Jun 9, 20264 EDGAR
  14. Jun 9, 20264 EDGAR
  15. Jun 9, 20263 EDGAR
  16. Jun 9, 20268-K EDGAR
  17. Jun 2, 20268-K EDGAR
  18. Jun 1, 20268-K EDGAR
  19. May 28, 2026SD EDGAR
  20. May 27, 20268-K EDGAR

The 295 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 6 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 6, 2025HAGGERTY GRETCHEN RDirectorBuy500$114.75$57.4KForm 4
Aug 5, 2025RANDLE STUART ADirectorBuy1,000$115.86$115.9KForm 4
Aug 5, 2025Krakauer Andrew ADirectorBuy1,000$115.25$115.2KForm 4
Aug 5, 2025Kelly LiamChairman, President & CEOBuy1,500$115.07$172.6KForm 4
Aug 5, 2025Ryu JaewonDirectorBuy1,500$115.00$172.5KForm 4
Aug 16, 2024RANDLE STUART ADirectorSale2,674$238.93$638.9KForm 4
Mar 5, 2024Hicks Cameron PCorp. VP & Chief HR OfficerSale7,401$225.00$1.7MForm 4
Dec 27, 2023Kelly LiamChairman, President & CEOSale26,256$250.23$6.6MForm 4
Nov 29, 2023POWELL THOMAS EExecutive Vice President & CFOSale13,952$222.88$3.1MForm 4
May 10, 2023RANDLE STUART ADirectorSale3,021$245.71$742.3KForm 4
Dec 30, 2022Kelly LiamChairman, President & CEOSale16,343$250.03$4.1MForm 4
Jun 7, 2022RANDLE STUART ADirectorSale3,014$283.31$853.9KForm 4
Dec 27, 2021Kelly LiamChairman, President & CEOSale8,987$330.00$3.0MForm 4
Nov 30, 2021Krakauer Andrew ADirectorBuy1,000$307.23$307.2KForm 4
Nov 10, 2021Hicks Cameron PCorp. VP & Chief HR OfficerSale3,600$350.00$1.3MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Liam J. KellyFormer President and Chief Executive Officer$1.1M$6.7M119
2025John R. DerenExecutive Vice President and Chief Financial Officer$548.9K$2.1M119
2025Jay K. WhiteFormer Corporate Vice President and President, Global Commercial$324.6K$2.0M119
2025James P. WintersCorporate Vice President, Manufacturing and Supply Chain$529.0K$1.7M119
2025Daniel V. LogueCorporate Vice President, General Counsel and Secretary$453.4K$1.6M119
2025Thomas E. PowellFormer Executive Vice President and Chief Financial Officer$171.9K$1.4M119
2025Cameron P. HicksCorporate Vice President and Chief Human Resources Officer$436.3K$1.3M119
2024Liam J. KellyFormer President and Chief Executive Officer$1.1M$9.2M119
2024Thomas E. PowellFormer Executive Vice President and Chief Financial Officer$659.5K$3.6M119
2024Jay K. WhiteFormer Corporate Vice President and President, Global Commercial$626.8K$2.4M119
2024James P. WintersCorporate Vice President, Manufacturing and Supply Chain$428.2K$2.1M119
2024Daniel V. LogueCorporate Vice President, General Counsel and Secretary$435.7K$2.0M119
2023Liam J. KellyFormer President and Chief Executive Officer$1.1M$9.0M119
2023Thomas E. PowellFormer Executive Vice President and Chief Financial Officer$631.2K$3.5M119
2023Jay K. WhiteFormer Corporate Vice President and President, Global Commercial$607.2K$2.4M119
2023Daniel V. LogueCorporate Vice President, General Counsel and Secretary$403.1K$1.8M119
2023James P. WintersCorporate Vice President, Manufacturing and Supply Chain$404.4K$1.6M119

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.5,431,818$688.5M0.0%+39,827
Jupiter Topco LLC4,342,512$550.5M0.2%New
Vanguard Portfolio Management LLC2,416,998$306.4M0.0%−21,185
Vanguard Capital Management LLC1,995,717$253.0M0.0%+11,893
Sessa Capital IM, L.P.1,526,228$193.5M3.3%No change
State Street Corp1,484,039$188.1M0.0%−18,818
Millennium Management LLC1,442,103$182.8M0.1%+760,045
Fuller & Thaler Asset Management, Inc.1,320,946$167.4M0.5%−43,004
Dimensional Fund Advisors LP1,152,695$146.1M0.0%+155,551
Citadel Advisors LLC1,140,950$144.6M0.1%−30,146
Geode Capital Management, LLC1,039,977$131.9M0.0%+41,557
Cooke & Bieler LP1,011,666$128.2M1.5%−131,008
Goldman Sachs Group Inc905,779$114.8M0.0%+707,189
Holocene Advisors, LP886,281$112.3M0.3%+470,946
Irenic Capital Management LP870,000$110.3M7.9%No change
Abrams Bison Investments, LLC793,000$100.5M4.9%−207,000
Norges Bank684,425$86.8M0.0%New
Pzena Investment Management LLC603,206$76.5M0.2%−95,919
Morgan Stanley591,301$75.0M0.0%+55,122
Invesco Ltd.573,914$72.7M0.0%+438,868
River Road Asset Management, LLC548,173$69.5M0.8%−373,943
Charles Schwab Investment Management Inc534,218$67.7M0.0%+14,433
Arrowstreet Capital, Limited Partnership490,277$62.1M0.0%−148,484
Bank Of America Corp /de/482,457$61.2M0.0%+36,499
Capital International Investors468,615$59.4M0.0%+12,790

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

13 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jul 22, 2025Lisa C. McClainRepublican, HouseSale$1,001 - $15,000+11.4%Report
Jul 16, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000−10.5%Report
Feb 25, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$1,001 - $15,000+57.7%Report
Jul 12, 2023Daniel S. GoldmanDemocratic, HouseSale$15,001 - $50,000+121.1%Report
Apr 10, 2023Daniel S. GoldmanDemocratic, HouseBuy$15,001 - $50,000−139.4%Report
Nov 30, 2022Susie LeeDemocratic, HouseSale$1,001 - $15,000+134.5%Report
Jun 28, 2021Susie LeeDemocratic, HouseBuy$1,001 - $15,000−149.0%Report
Dec 16, 2020Susie LeeDemocratic, HouseBuy$1,001 - $15,000−176.2%Report
Dec 8, 2020Susie LeeDemocratic, HouseBuy$1,001 - $15,000−175.0%Report
Dec 3, 2020Susie LeeDemocratic, HouseBuy$1,001 - $15,000−176.6%Report
May 19, 2020Susie LeeDemocratic, HousePartial sale$1,001 - $15,000+227.2%Report
Apr 28, 2020Susie LeeDemocratic, HousePartial sale$1,001 - $15,000+232.4%Report
Dec 27, 2019Susie LeeDemocratic, HousePartial sale$1,001 - $15,000+204.6%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Teleflex is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTELEFLEX INC2
  • CIK0000096943
  • Employer ID (EIN)23-114793917
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
  • Incorporated inDelaware17
  • Fiscal year endsDecember 312
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address550 E Swedesford Rd, Suite 400, Wayne, PA 190872
  • Phone610-225-68002
  • Shares outstanding42,372,397 as of Aug 4, 202615
  • Public float$2.3B as of Jun 29, 202517
  • AuditorPricewaterhouseCoopers LLP, Philadelphia, Pennsylvania PCAOB ID 238; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceJan 5, 19942
  • Filings1,838 in all: 4 (919), 8-K (323), 10-Q (98), 5 (84), SC 13G/A (84), 4/A (48), 3 (41), DEF 14A (33)2
    All 41 form types

    10-K (31), 11-K (22), SC 13G (19), UPLOAD (16), SCHEDULE 13G/A (14), SD (13), S-8 (11), 8-K/A (10), CORRESP (10), 144 (5), 424B2 (5), FWP (5), PRE 14A (5), 3/A (4), ARS (4), SC 13D (4), 424B5 (3), DEFA14A (3), DFAN14A (3), SCHEDULE 13G (3), 10-K405 (2), 10-Q/A (2), POSASR (2), S-3ASR (2), SC 13D/A (2), 424B3 (1), 5/A (1), 8-A12B (1), 8-A12B/A (1), EFFECT (1), NT 10-K (1), PX14A6G (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Feb 27, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 13, 2026
    Latest 8-K (8-K) Sep 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $1.00 per shareTFXNew York Stock Exchange

From the cover page of the 10-K filed Feb 27, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks Teleflex names in Item 1A of its 10-K filed Feb 27, 2026: 34 risks under these headings, as written.17

  • Risks Relating to our Business and Operations
  • We face strong competition. Our failure to successfully develop and market new products could adversely affect our business.
  • Our customers depend on third party coverage and reimbursements, and the failure of healthcare programs to provide sufficient coverage and reimbursement for our medical products could adversely affect us.
  • We are subject to extensive government regulation, which may require us to incur significant expenses to ensure compliance. Our failure to comply with those regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • We are subject to healthcare fraud and abuse laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.
  • We may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions, and may experience business disruptions associated with restructuring, facility consolidations, realignment, cost reduction and other strategic initiatives.
  • The strategic transformation that we are currently implementing may not have the intended results and may be harmful to our business.
  • Disruptions in sterilization of our products or regulatory initiatives further restricting the use of ethylene oxide in sterilization facilities could adversely affect our results of operations and financial condition.
  • A significant portion of our U.S. revenues is derived from sales to distributors, and “destocking” activity by these distributors can adversely affect our revenues and results of operations.
  • We may incur material losses and costs as a result of product liability and warranty claims, as well as product recalls, any of which may adversely affect our results of operations and financial condition. Furthermore, our reputation as a medical device company may be damaged if one or more of our products are, or are alleged to be, defective.
  • Volatility in domestic and global financial markets, including inflation, interest rate fluctuations, and global supply chain disruptions, could adversely impact our results of operations, financial condition and liquidity.
  • Our strategic initiatives, including acquisitions, may not produce the intended growth in revenue and operating income, which could have a material adverse effect on our operating results.
The other 23 risks
  • Our results of operations and financial condition may be adversely affected by public health epidemics or pandemics, as occurred with respect to the recent COVID-19 epidemic and pandemic.
  • Health care reform may have a material adverse effect on our industry and our business.
  • We are subject to risks associated with our non-U.S. operations.
  • Future material impairments to the value of our goodwill or other intangible assets would negatively affect our operating results.
  • Foreign currency exchange rate, commodity price and interest rate fluctuations may adversely affect our results.
  • Fluctuations in our effective tax rate and changes to tax laws may adversely affect us.
  • An interruption in our manufacturing or distribution operations or our supply of raw materials may adversely affect our business.
  • Our ability to attract, train, develop and retain key employees is important to our success.
  • We could be adversely affected by our ongoing CEO transition.
  • Our failure to maintain strong relationships with physicians and other health care professionals could adversely affect us.
  • Our technology is important to our success, and our failure to protect our intellectual property rights could put us at a competitive disadvantage.
  • Our products or processes may infringe the intellectual property rights of others, which may cause us to pay unexpected litigation costs or damages or prevent us from selling our products.
  • Other pending and future litigation may involve significant costs and adversely affect our business.
  • Disruption of critical information systems or material breaches in the security of our systems may adversely affect our business and customer relationships.
  • Our operations expose us to the risk of material environmental and health and safety liabilities.
  • The effects of climate change or legal, regulatory or market measures intended to address climate change could adversely affect our business, results of operations, financial condition and cash flows.
  • Our workforce covered by collective bargaining and similar agreements could cause interruptions in our provision of products and services.
  • Risks Relating to our Financing Arrangements
  • Our substantial indebtedness could adversely affect our business, financial condition or results of operations.
  • Our debt agreements impose restrictions on our business, which could prevent us from pursuing business opportunities and taking other desirable corporate actions, and may adversely affect our ability to respond to changes in our business and manage our operations.
  • Under our cross-currency swap agreements, a meaningful decline in the U.S. dollar to certain exchange rates could have a material adverse effect on our cash flows.
  • Risks Relating to Ownership of our Common Stock
  • We may issue additional shares of our common stock or instruments convertible into our common stock, which could cause the price of our common stock to decline.
  • We may not pay dividends on our common stock in the future.
  • Certain provisions of our corporate governing documents, Delaware law and our Senior Notes could discourage, delay, or prevent a merger or acquisition.

Legal proceedings

We are party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability and product warranty, intellectual property, commercial disputes, acquisition and divestiture related matters, contracts, employment, environmental and other matters. As of December 31, 2025 and 2024, we accrued liabilities of $0.3 million and $0.8 million, respectively, in connection with these matters, representing our best estimate of the cost within the range of estimated possible loss that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, we do not believe that any such actions are likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or cash flows. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or cash flows. See Note 17 to the consolidated financial statements included in this Annual Report on Form 10-K for additional information.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
    SEC EDGAROther events
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
    SEC EDGAROther events
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109
  110. 110
  111. 111
  112. 112
  113. 113
  114. 114
  115. 115
  116. 116
  117. 117
  118. 118
  119. 119